Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation by Tol, J. et al.
SHORT REPORT
Gastrointestinal ulceration as a possible side effect
of bevacizumab which may herald perforation
J. Tol & A. Cats & L. Mol & M. Koopman &
M. M. E. M. Bos & J. J. M. van der Hoeven &
N. F. Antonini & J. H. J. M. van Krieken & C. J. A. Punt
Received: 17 December 2007 /Accepted: 19 February 2008 /Published online: 12 March 2008
# The Author(s) 2008
Summary Chemotherapy plus bevacizumab is currently
considered as the standard 1st line treatment of advanced
colorectal cancer (ACC). Whereas GI perforation is a
known side effect of bevacizumab, the development of GI
ulcers has not been reported. We identified 18 patients with
ACC who participated in a phase III multicentre trial which
included chemotherapy and bevacizumab, who developed a
GI ulcer (n=6), perforation (n=8) or both (n=4). The risk
of developing a symptomatic GI ulcer or perforation was
1.3% and 1.6%, respectively. Central review of the his-
tology specimens showed ulceration and/or granulation
tissue with neovascularisation. The majority (89%) of
events developed early during treatment. Given these
observations, as well as the relationship between VEGF
and mucosal injury healing, we suggest that GI ulcers may
occur as a side effect of treatment with bevacizumab and
may herald perforation.
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Introduction
Colorectal cancer is the second most common cause of
cancer deaths worldwide with 492,000 related deaths in
2000 [1]. Approximately 50% of patients will eventually
develop distant metastases, for which usually palliative
systemic treatment is administered. Over the past decades
the treatment options for patients with advanced colorectal
cancer (ACC) have changed considerably. Currently avail-
able cytotoxic drugs, the fluoropyrimidines (5FU, UFT and
capecitabine), oxaliplatin and irinotecan have improved the
median overall survival from 8 months with supportive care
alone to approximately 17–19 months [2]. Recently, a new
class of agents has been developed that inhibits signal
transduction pathways, and which are usually referred to as
targeted therapy. In ACC two drugs of this class are
currently being used in the clinic: inhibitors of the
epidermal growth factor receptor (EGFR) and of the
vascular endothelial growth factor (VEGF) [3]. VEGF is a
potent angiogenic factor that exerts its effect by binding to
one or more of the VEGF receptors (VEGFR), leading to
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ways. In addition to the stimulation of neoangiogenesis,
VEGF shows significant mitogenic activity for arterial,
venous and lymphatic endothelial cells and plays a role in
endothelial cell proliferation, vascular permeability and the
inhibition of apoptosis [4]. Bevacizumab (Avastin®) is a
humanized monoclonal antibody to VEGF. The addition of
bevacizumab to fluoropyrimidine-containing chemotherapy
significantly prolongs the median overall survival (OS) in
previously untreated patients with ACC [5, 6]a n di s
currently considered as the standard first-line treatment. In
2nd line, bevacizumab also shows a significant increase in
OS when added to chemotherapy [7]. Bevacizumab is
generally well tolerated. The most common toxicities are
hypertension and proteinuria. Arterial thromboembolic
events, bleeding diathesis (mainly gastrointestinal bleeding)
and gastrointestinal perforations have consistently been
reported but at a low frequency. The focus of bleeding has
been located along the entire digestive tract. In patients with
ACC with their primary tumour in situ and who were
treated with chemotherapy plus bevacizumab, the primary
tumour was the focus of bleeding in 50% (8/16) of the
patients [8]. The overall incidence of GI perforation in large
series of ACC patients is approximately 1–2% [6, 8, 9]. In
phase II studies with bevacizumab and chemotherapy the
incidence of GI perforations was 6% in 47 patients with
advanced gastric or gastroesophageal junction carcinoma
[10], and 8% in 52 patients with advanced pancreatic
cancer [11]. In the latter study, one patient developed
ulceration at the site of the gastrojejunostomy anastomosis
with secondary perforation at this site. In advanced ovarian
cancer, a large variation in the incidence of GI perforations
after treatment with bevacizumab either as monotherapy or
combined with chemotherapy has been reported, ranging
from 0% to 15.4% [12]. The intra-abdominal spread of
ovarian cancer metastases compared to other cancer types
may play a role in the higher incidence of perforations in
this disease. The etiology of GI perforations occurring upon
treatment with bevacizumab is unknown. Perforations may
develop at the site of the primary tumour or elsewhere in
the digestive tract, amongst others in the stomach or
duodenum [9]. In patients without previous resection of
the primary tumour, the site of perforation is related to the
primary tumour site in 50% of the patients [9]. Predisposing
factors for GI perforation are acute diverticulitis, GI
obstruction, primary tumour in situ, abdominal carcinoma-
tosis and prior abdominal or pelvic radiotherapy [13].
Here we present a series of patients who developed a
symptomatic GI ulcer, perforation, or both during treatment
with bevacizumab plus chemotherapy in a prospective
phase III study. We postulate that GI ulcers are an adverse
effect of treatment with bevacizumab and may herald
perforation.
Patients and methods
Patients with ACC were treated within a multicentre
phase III study (CAIRO2, CKTO 2005-02) of the Dutch
Colorectal Cancer Group (DCCG), and were randomized
between capecitabine 1000 mg/m
2 orally twice daily day
1–14, oxaliplatin 130 mg/m
2 i.v. day 1, and bevacizumab
7.5 mg/kg i.v. day 1 (arm A), and the same treatment but
with the addition of weekly cetuximab (a chimaeric
antibody against the epidermal growth factor receptor)
400 mg/m
2 i.v. in week 1 and 250 mg/m
2 i.v. weekly
thereafter (arm B) [14]. All cycles were given q 3 weeks.
Inclusion criteria included a histologically proven ACC
with irresectable distant metastases, the presence of at least
o n em e a s u r a b l ed i s e a s ep a rameter, WHO performance
status 0 or 1, and adequate organ functions. Main exclusion
criteria were prior chemotherapy for advanced disease,
bleeding diathesis or coagulation disorders, uncontrolled
hypertension, a serious non-healing wound or ulcer, and
major surgery within 28 days prior to the start of treatment.
Accrual of 755 patients was completed in December 2006.
During follow-up we observed several cases of symptom-
atic GI ulcers and perforations. GI ulcers without perfora-
tion were identified during evaluation of abdominal pain or
GI bleeding. To investigate a possible relationship between
these events, all relevant clinical data of these patients were
collected. Available tissue material of ulcers or perforations
was centrally reviewed by a pathologist (JvK).
Results
Eighteen patients presented with a symptomatic GI ulcer
(Fig. 1)( n=6), perforation(n=8) or a perforated ulcer (n=4;
Table 1). Patient characteristics are shown in Table 2.
Median age was 64 years (range 50–73). The incidence of
GI ulcer, perforation, or perforated ulcer development in the
present study was 0.8%, 1.0% and 0.5% respectively. The
overall risk of the development of an ulcer with or without
perforation, or a perforation with or without an ulcer was
1.3% and 1.6%, respectively. The incidence of events was
higher in the cetuximab treatment arm (ulcers: two versus
four; perforation: five versus three; perforated ulcers: three
versus one, respectively). However the small difference in a
low number of events does not allow further conclusions.
Four ulcers developed in the upper digestive tract and two
ulcers developed in the lower digestive tract, of which one at
the site of anastomosis at 5 months after colon resection. All
eight perforations were located in the lower digestive tract, of
which six at the site of the primary tumour or local
recurrence. One perforated ulcer developed in the duodenum,
two at the site of primary anastomosis 16 months and 3 years
after rectum resection, respectively, and one patient devel-
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along the entire digestive tract. Both patients who developed
a perforated ulcer at the site of the anastomosis following
anterior resection previously underwent preoperative radio-
therapy on the pelvic region. Sixteen (89%) events (five
ulcers, seven perforations and all four perforated ulcers)
developed within the first 15 weeks after the start of
treatment. The histological diagnosis was confirmed upon
pathologic review in all 13 patients of whom tissue speci-
mens were available (five ulcers, four perforations and all
four perforated ulcers). One tumour showed deep ulceration
with necrosis at the side of perforation (patient 15). Since no
tissue was available from 4 perforations, the presence of
ulceration surrounding the perforation could not be assessed
in these patients. As bevacizumab is an inhibitor of
angiogenesis, and as we presumed that the inhibition of
angiogenesis was related to the development of ulcers and
perforations, special attention was focussed at the blood
vessels surrounding the ulcer or perforation. No special
features were seen and the expected neovascularisation
Table 2 Patient characteristics
Patient Sex Age Treatment arm Site of primary Primary in situ Relevant comedication Prior radiotherapy on pelvis
1M5 8 A C − – −
2 M 68 A C + PPI, NSAID −
3M5 7 A R − PPI, S −
4M6 6 B R S + – −
5M6 2 A C − PPI,NSAID −
6 M 66 B C + – −
7M5 0 B R − PPI, NSAID +
8F 7 3 B C − PPI −
9M7 1 A R − PPI, S +
10 F 73 B C − PPI, NSAID −
11 F 57 B C + PPI −
12 M 60 B R − – −
13 M 58 A C + – −
14 M 72 A C + NSAID, S −
15 M 67 B C − – −
16 M 57 A C + NSAID −
17 M 53 B C + NSAID −
18 F 67 B R − – +
Treatment arm A: capecitabine, oxaliplatin, bevacizumab; treatment arm B: capecitabine, oxaliplatin, bevacizumab and cetuximab
M Male, F female, C colon, R rectum, RS rectosigmoid, PPI protonpump inhibitor, NSAID non steroidal anti-inflammatory drug, S steroid
Table 1 Characteristics of the
event
U Ulcer, P perforation, Yes
primary tumour or local recur-
rence, No unrelated, A event at
the site of anastomosis after
resection of the primary tumour
Patients Ulcer/perforation Number of
cycles received
Site of event Relationship
with tumour
1 U 4 Stomach No
2 U 2 Duodenum No
3 U 4 Colon A
4 U 12 Stomach No
5 U 1 Ileum No
6 U 5 Stomach No
7 U + P 3 Colon A
8 U + P 2 Duodenum No
9 U + P 3 Colon A
10 U + P 1 Duodenum, small intestine, colon Yes
11 P 4 Colon Yes
12 P 3 Ileum A
13 P 11 Colon Yes
14 P 1 Colon Yes
15 P 4 Colon/duodenum Yes
16 P 1 Colon Yes
17 P 2 Colon Yes
18 P 2 Colon No
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immunostaining for macrophages (performed on tissue of 10
patients), CD31 and CD34 for assessing vascularity (one
patient) and CMV staining (three patients) did not reveal any
abnormalities. No Helicobacter pylori colonisation was
found in the gastric and duodenal biopsies by histology. In
all five patients developing a perforation with a primary
tumour in situ, the perforation was located within the
primary tumour. Seven perforations occurred in patients
after resection of the primary tumour (58%), in whom the
anastomosis was the site of perforation in three patients. In
order to assess other known risk factors for ulceration, the
use of relevant comedication (protonpump inhibitors (PPI),
non-steroidal anti-inflammatory drugs (NSAID) and steroids)
was recorded. Out of seven patients with localisation of an
ulcer or perforation in the upper abdominal tract, two
patients used NSAID in combination with prophylactic use
of PPI at the time of randomisation and a third patient used
PPI for unknown indication. Three patients used oral steroids
at the time of randomisation.
Discussion
We observed a symptomatic GI ulcer in 10 patients with
ACC (1.3%) who were included in a phase III study that
involvedatotalof755patientstreatedwithchemotherapyand
bevacizumabwithorwithoutcetuximab.Pathologicreviewof
the ulcers did not show unusual findings. This incidence is
higher than the 0.1% that has been reported for the general
population [15]. In four of these patients a perforated ulcer
was diagnosed. Since GI perforation is a known side effect
of bevacizumab [6, 8, 9], and ulcers have not been reported
as a complication of any systemic anticancer treatment, these
findings prompted us to assess the possible relationship
between ulcer development and treatment with bevacizumab,
as well as between ulcer development and perforation.
Several preclinical studies have been performed on the role
of VEGF in GI mucosa and ulcer healing. Neoangiogenesis in
general, and VEGF in particular, play an important role in the
healing of GI ulcers [16]. In animal models injection of
plasmid-DNA encoding VEGF stimulates the healing of
gastric ulcers [17]. Moreover, the level of VEGF expression
correlates with the size and depth of stress-induced gastric
ulcers in murine models. Higher levels of VEGF expression
are associated with a decrease in ulcer size and depth [18].
Infusion of an anti-VEGF antibody in rats results in a
significantly delayed healing of gastric erosions [19]. Lastly,
the inhibitory effect of bevacizumab on wound healing is
well established [20], and a non-significant trend for an
increased incidence of wound healing complications has been
observed during bevacizumab treatment [21]. These data
support a role for anti-VEGF therapy in ulcer development.
The incidence of perforation in our study was compara-
ble to earlier published data [6, 8, 9]. In four out of 12
patients who presented with a perforation an ulcer was
demonstrated at the site of perforation. It should be noted
that tissue from perforated sites was only available from
eight patients. Furthermore, ulceration at the site of a
primary tumour may be a non-specific finding as ulceration
and deep necrosis are typical features in malignancies. The
aetiology of perforations during bevacizumab treatment is
unknown. Since the majority of perforations has been
observed at the site of the primary tumour, mucosal injury
may be considered as a predisposing factor. In patients with
a resected primary tumour, mucosal damage is present at
the site of anastomosis. We observed one ulcer, two
perforated ulcers and one perforation at the site of anasto-
mosis after bowel resection.
Taken together, these data suggest a relationship between
mucosal injury and the development of GI ulceration or
perforation. It has been postulated that the development of
GI perforations in patients treated with bevacizumab might
be the result of mesenteric ischaemia due to the cholesterol
emboli syndrome [21]. Since ulceration is a well-known
feature of mesenteric ischaemia, this is in agreement with
our hypothesis.
NSAID use has been associated with a risk of GI
ulceration, which is not limited to the upper GI tract [22].
Six patients with a distal GI ulcer or perforation used
NSAID and three patients used steroids. However, a causal
relationship is unlikely considering the frequent use of
these drugs and the low incidence of symptomatic distal GI
ulcers in the general population. Further pathological
studies of perforated sites are warranted to confirm
ulceration as a predisposing factor for perforation. Of note,
a perforated ulcer at the site of anastomosis during
treatment with bevacizumab has been reported in a patient
with pancreatic cancer [11].
Fig. 1 Gastric ulcer at endoscopy in patient 1
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early during treatment is consistent with observations in GI
perforations by Sugrue et al. [13]. This early occurrence
also supports a causal relationship between the develop-
ment of ulcers and the use of bevacizumab.
In conclusion, we identified symptomatic GI ulcers as a
possible side effect of treatment with bevacizumab in
patients with ACC. This is supported by the relatively high
incidence of ulcers in our study population, the early
occurrence of ulcers during bevacizumab treatment, the
important role of VEGF in ulcer and mucosal injury healing
and the inhibitory effect of bevacizumab on wound healing.
We suggest that GI ulcers may herald perforation. Pre-
existent mucosal lesions may be preferential localisations
for the development of ulcers as well as perforations. We
recommend performing endoscopic evaluation in any
patient during treatment with bevacizumab upon presenta-
tion with symptoms that may be related to a GI ulcer, and
to closely examine tissue specimens from perforated sites
for the presence of ulcers. When further studies confirm
the relationship between ulcer development and perfora-
tion, patients should be carefully monitored for signs
or symptoms related to ulcers, and should an ulcer be
diagnosed the administration of bevacizumab should be
permanently discontinued.
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